HBIO
Harvard Bioscience, Inc. NASDAQ Listed Mar 19, 2001$6.06
Mkt Cap $26.9M
52w Low $3.79
55.6% of range
52w High $7.87
50d MA $6.06
200d MA $5.71
P/E (TTM)
-2.8x
EV/EBITDA
—
P/B
2.0x
Debt/Equity
3.2x
ROE
-412.8%
P/FCF
4.8x
RSI (14)
42.50
ATR (14)
$0.42
Beta
1.50
50d MA
$6.06
200d MA
$5.71
Avg Volume
27.5K
Harvard Bioscience, Inc. develops, manufactures, and sells technologies, products, and services that enables fundamental research, discovery, and pre-clinical testing for drug development in the United States and internationally. The company offers cellular and molecular technology instruments, such as syringe and peristaltic pump products, as well as a range of instruments and accessories for tissue and organ-based lab research, including surgical products, infusion systems, and behavior research systems; and spectrophotometers, microplate readers, amino acid analyzers, gel electrophoresis equipment, and electroporation and electrofusion instruments. It also engages in the development and manufacture of precision scientific measuring instrumentation and equipment, which cover data acquisition systems with custom amplifier configurations for cellular analysis, micro electrode array solutions for in vivo recordings, and vitro-systems for extracellular recordings; and offers preclinical products. The company markets its products through sales organizations, websites, catalogs, and distributors to research scientists in pharmaceutical and biotechnology companies, universities, hospitals, and government laboratories, as well as to contract research organizations, academic labs, and government researchers. It primarily sells its products under Harvard Apparatus, DSI, Ponemah, Buxco, Biochrom, BTX, and MCS brand names. The company was founded in 1901 and is headquartered in Holliston, Massachusetts.
84 October Hill Road · Holliston, MA 01746 · US
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mar 12, 2026 | AMC | 0.35 | -0.01 | -102.9% | 4.94 | -4.9% | -4.3% | +5.9% | -2.8% | +0.2% | +14.8% | — |
| Nov 6, 2025 | AMC | 0.01 | -0.01 | -300.0% | 5.46 | -5.7% | -0.5% | +7.0% | +4.6% | +2.3% | -6.4% | — |
| Aug 11, 2025 | AMC | -0.03 | -0.01 | +60.0% | 4.79 | -1.7% | +0.8% | +3.5% | -2.2% | +8.2% | -4.5% | — |
| May 12, 2025 | AMC | -0.04 | -0.01 | +75.0% | 3.52 | +1.1% | +5.4% | -6.7% | +2.6% | -4.2% | +0.3% | — |
| Mar 12, 2025 | AMC | 0.05 | 0.06 | +20.0% | 6.85 | +3.6% | -6.6% | +1.2% | +7.3% | -3.0% | +2.2% | — |
| Nov 7, 2024 | AMC | -0.01 | -0.02 | -174.0% | 23.90 | +0.4% | +7.5% | -4.7% | -6.9% | -4.8% | +5.5% | — |
| Aug 8, 2024 | AMC | 0.05 | -0.03 | -160.0% | 31.20 | -0.6% | -6.7% | +1.4% | -2.0% | -2.8% | +1.8% | — |
| May 7, 2024 | AMC | 0.02 | 0.02 | -14.1% | 37.50 | -2.7% | -1.9% | -3.3% | -0.8% | -4.0% | +1.2% | — |
| Mar 7, 2024 | AMC | 0.05 | 0.04 | -20.0% | 45.10 | +1.6% | -2.0% | -1.4% | -2.1% | +2.8% | -2.3% | — |
| Nov 7, 2023 | AMC | 0.04 | 0.01 | -75.0% | 42.50 | +0.2% | -1.4% | -2.1% | -2.4% | +2.3% | +6.6% | — |
| Aug 8, 2023 | AMC | 0.06 | 0.04 | -33.3% | 44.30 | -0.2% | -1.8% | -2.8% | +1.7% | -7.0% | +6.0% | — |
| Apr 25, 2023 | AMC | 0.05 | 0.06 | +20.0% | 52.50 | +0.8% | +6.5% | +1.8% | +0.5% | +4.0% | +2.4% | — |
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mar 16 | Benchmark | Maintains | Speculative Buy → Speculative Buy | — | $4.73 | $4.45 | -5.9% | +5.9% | -2.8% | +0.2% | +14.8% | -5.9% |
| Mar 13 | Benchmark | Maintains | Speculative Buy → Speculative Buy | — | $4.94 | $4.70 | -4.9% | -4.3% | +5.9% | -2.8% | +0.2% | +14.8% |
| Sep 10 | Benchmark | Maintains | Speculative Buy → Speculative Buy | — | $4.38 | $4.52 | +3.2% | +2.5% | -1.1% | -0.5% | -0.7% | +10.5% |
| May 13 | Benchmark | Maintains | Speculative Buy → Speculative Buy | — | $3.52 | $3.56 | +1.1% | +5.4% | -6.7% | +2.6% | -4.2% | +0.3% |
| Apr 9 | KeyBanc Capital Markets | Downgrade | Overweight → Sector Weight | — | $3.66 | $3.71 | +1.4% | +25.4% | -15.9% | +3.6% | -1.0% | -0.3% |
| Apr 8 | KeyBanc Capital Markets | Downgrade | Overweight → Sector Weight | — | $3.81 | $4.60 | +20.7% | -3.9% | +25.4% | -15.9% | +3.6% | -1.0% |
| Mar 24 | Benchmark | Maintains | Speculative Buy → Speculative Buy | — | $6.36 | $6.51 | +2.4% | -5.8% | -1.2% | +3.2% | -1.8% | +1.7% |
| Jun 22 | Benchmark | Maintains | Speculative Buy → Speculative Buy | — | $59.80 | $59.90 | +0.2% | +1.5% | -2.1% | -0.7% | -1.2% | -3.9% |
| Apr 26 | Benchmark | Maintains | Buy → Buy | — | $52.50 | $52.90 | +0.8% | +6.5% | +1.8% | +0.5% | +4.0% | +2.4% |
| Apr 26 | KeyBanc Capital Markets | Maintains | Overweight → Overweight | — | $52.50 | $52.90 | +0.8% | +6.5% | +1.8% | +0.5% | +4.0% | +2.4% |
| Mar 10 | Benchmark | Maintains | Buy → Buy | — | $26.60 | $27.30 | +2.6% | +0.4% | -4.1% | +4.3% | -1.1% | +5.7% |
| Nov 9 | KeyBanc Capital Markets | Maintains | Overweight → Overweight | — | $24.20 | $23.10 | -4.5% | -9.5% | +6.8% | +2.6% | +10.4% | -9.4% |
| Aug 5 | KeyBanc Capital Markets | Maintains | Overweight → Overweight | — | $36.00 | $35.70 | -0.8% | -1.9% | -3.7% | -1.2% | -0.9% | -1.2% |
| Nov 10 | KeyBanc | Maintains | Overweight → Overweight | — | $37.70 | $35.20 | -6.6% | +3.4% | +0.5% | -0.3% | +3.6% | +0.2% |
| Nov 10 | KeyBanc Capital Markets | Maintains | Overweight → Overweight | — | $37.70 | $35.20 | -6.6% | +3.4% | +0.5% | -0.3% | +3.6% | +0.2% |
| Feb 27 | Benchmark | Maintains | Speculative Buy → Speculative Buy | — | $29.60 | $30.50 | +3.0% | +11.1% | -1.5% | -3.7% | -4.5% | +0.3% |
| Nov 17 | Singular Research | Maintains | Buy → Buy | — | $26.00 | $26.00 | +0.0% | -1.9% | +2.0% | -1.9% | -2.0% | +4.0% |
| Jul 28 | Benchmark | Maintains | Buy → Buy | — | $49.40 | $50.30 | +1.8% | +1.4% | -0.8% | -2.0% | +0.4% | +0.6% |
| Nov 26 | Sidoti & Co. | Upgrade | Neutral → Buy | — | $43.10 | $44.00 | +2.1% | +3.7% | +0.7% | +1.3% | -3.3% | +0.2% |
No insider trades available.
8-K · 2.02
!! High
Harvard Bioscience, Inc. -- 8-K 2.02: Earnings Results
May 12
8-K · 7.01
! Medium
Harvard Bioscience, Inc. -- 8-K 7.01: Regulation FD Disclosure
May 12
8-K · 7.01
! Medium
Unknown — 8-K 7.01: Regulation FD Disclosure
Harvard Bioscience disclosed updated investor materials indicating management believes the company warrants renewed investor attention, though the incomplete document prevents assessment of specific operational or financial developments affecting stock outlook.
Mar 17
8-K
Unknown — 8-K Filing
Harvard Bioscience's improved Q4 2025 results driven by better product mix and cost controls suggest operational efficiency gains that could support margin expansion and stock valuation if these improvements sustain.
Mar 12
8-K · 5.02
!!! Very High
Unknown — 8-K 5.02: Executive Change
New CFO appointment effective March 6, 2026 could signal leadership stability or strategic direction changes, warranting investor attention to management experience and company's financial guidance updates.
Mar 10
8-K · 8.01
!! High
Harvard Bioscience Inc -- 8-K 8.01: Material Event / Announcement
Harvard Bioscience implemented a 1-for-10 reverse stock split effective immediately, consolidating shares to boost stock price and maintain Nasdaq listing compliance.
Mar 6
8-K
Harvard Bioscience Inc -- 8-K Filing
Harvard Bioscience reported Q4 2025 preliminary results and outlined a long-term strategy leveraging its research tools portfolio to achieve sustainable growth and enhance shareholder value.
Feb 10
Institutional (13F) — Top 18
All ↗
| # | Manager | Shares | Value | Chg | Period |
|---|---|---|---|---|---|
| 1 | Weber Capital Management Llc /adv | 320,037 | $2M | New | Mar 2026 |
| 2 | Acadian Asset Management Llc | 179,614 | $873K | New | Mar 2026 |
| 3 | Vanguard Capital Management Llc | 163,313 | $795K | New | Mar 2026 |
| 4 | Two Sigma Investments, Lp | 114,117 | $556K | New | Mar 2026 |
| 5 | Renaissance Technologies Llc | 101,427 | $494K | New | Mar 2026 |
| 6 | Millennium Management | 46,332 | $226K | New | Mar 2026 |
| 7 | Rbf Capital, Llc | 32,000 | $156K | New | Mar 2026 |
| 8 | Williams & Novak, Llc | 27,052 | $138K | New | Mar 2026 |
| 9 | Essex Investment Management Co Llc | 27,021 | $132K | New | Mar 2026 |
| 10 | Bank Of New York Mellon Corp | 10,230 | $50K | New | Mar 2026 |
| 11 | Ubs Group Ag | 8,405 | $41K | New | Mar 2026 |
| 12 | Jpmorgan Chase & Co | 4,463 | $21K | New | Mar 2026 |
| 13 | Fmr Llc | 3,274 | $16K | New | Mar 2026 |
| 14 | Royal Bank Of Canada | 855 | $4K | New | Mar 2026 |
| 15 | Brown Shipley& Co Ltd | 478 | $2K | New | Mar 2026 |
| 16 | Bnp Paribas Financial Markets | 68 | $331 | New | Mar 2026 |
| 17 | Pnc Financial Services Group, Inc. | 14 | $68 | New | Mar 2026 |
| 18 | Cwm, Llc | 4 | $19 | New | Mar 2026 |
Mutual Funds / ETFs (N-PORT) — Top 4
All ↗
| # | Fund | Shares | Value | Period |
|---|---|---|---|---|
| 1 | ACUITAS US MICROCAP FUND | 8,782 | $43K | Mar 2026 |
| 2 | Gabelli Global Mini Mites Fund | 4,000 | $19K | Mar 2026 |
| 3 | BlackRock Advantage Small Cap Core Fund | 307 | $188 | Feb 2026 |
| 4 | Guggenheim Active Allocation Fund | 234 | $144 | Feb 2026 |
Valuation
Market Cap
$26.9M
Enterprise Value
$54.2M
P/E (TTM)
-2.75x
Forward P/E
—
PEG Ratio
-0.00x
P/B
1.96x
P/S
0.31x
P/FCF
4.79x
EV/EBITDA
—
Shares Out
4.4M
Financials (TTM)
Revenue
$85.5M
Net Income
-$9.8M
EBITDA
-$1.9M
Free Cash Flow
$5.6M
Op Cash Flow
$6.7M
EPS Basic
$-12.80
EPS Diluted
$-2.20
EPS Forward
$-1.38
Gross Margin
57.1%
Op Margin
1.4%
Net Margin
-11.4%
Balance Sheet
Total Assets
$80.1M
Total Liab.
$66.3M
Total Equity
$13.7M
Cash
$8.6M
LT Debt
$35.9M
Book Value/Sh
$3.09
Debt/Equity
3.22x
Current Ratio
2.20
Quick Ratio
1.25
Returns & Growth
ROE
-412.8%
ROA
-70.8%
ROIC
-1.0%
Rev Growth YoY
-8.1%
EPS Growth YoY
-357.1%
Price Returns
2W
+6.5%
1M
-7.8%
3M
-4.2%
6M
-22.7%
12M
+25.9%
Technicals
52W High
$7.87
52W Low
$3.79
50d MA
$6.06
200d MA
$5.71
RSI (14)
42.50
ATR (14)
$0.42
Beta
1.50
Avg Volume
27K
Dividends
Div Rate
$0.00
Div Yield
—
Frequency
—
Ex-Div Date
—
Analyst Price Targets
Consensus
$6.00
High
$6.00
Low
$6.00
Median
$6.00
Data updated apr 25, 2026 1:03pm
· Source: financialmodelingprep.com